ADANI-GROUP
15.2.2024 18:24:28 CET | Business Wire | Press release
International Rating agencies Moody’s (vide press release dated 13th February 2024) and S&P (vide press release dated 22nd January 2024) have affirmed and upgraded the outlook to “stable” for all the issuances for Adani complex issued in the international market by various Adani Portfolio companies.
This assures high credit quality with stable and predictable cashflows across all issuers of Adani complex. Adani Portfolio has the largest number of Investment Grade (BBB-/Baa3 and higher) rated issuances out of private companies in India and equivalent to India’s sovereign rating.
Additionally, Moody’s vide its press release dated 13th February 2024 stated that “the Group has completed a number of debt transactions, including refinancing as well as obtaining new loan facilities, demonstrating its continued access to debt capital at a reasonable cost. At the same time, several high-profile equity transactions by large institutional and strategic investors, such as GQG and Qatar Investment Authority, also demonstrated the Group's continued equity market access.
“[W]hilst an investigation by Securities and Exchange Board of India (SEBI) – India's securities market regulator - is still ongoing, the Supreme Court's decision to entrust SEBI to complete the investigation on the Adani Group and the court's view that there is no apparent regulatory failure attributable to SEBI have curbed the potential tail risk in a downside scenario.”
And S&P vide its press release dated 22nd January 2024 noted that “We believe the conclusion of most regulatory investigations into the Adani Group without evidence of wrongdoing has reduced downside risk.
“Repayment of all promoter loans linked to share prices, equity, and bank loans raised by multiple group entities at competitive rates reflects restored access to funding. In our view, rated entities Adani Electricity Mumbai Ltd. (AEML) and Adani Ports and Special Economic Zone Ltd. (APSEZ) enjoy good competitive positions, healthy cash flows, and adequate liquidity to meet their debt-servicing requirements.”
A summary of the rating upgrades is as detailed below -
Issuer Name |
Rating Agency |
Summary of Rating Action |
|
Rating |
Outlook |
||
Adani Ports and SEZ Limited |
S&P |
Reaffirmed at BBB- |
Upgraded to ‘Stable’ from ‘Negative’ |
Moody’s |
Reaffirmed at Baa3 |
Reaffirmed at ‘Stable’ |
|
Fitch |
Maintained at BBB- |
Maintained at ‘Stable’ |
|
Adani International Container Terminal Private Limited |
S&P |
Maintained at BBB- |
Maintained at ‘Stable’ |
Moody’s |
Reaffirmed at Baa3 |
Reaffirmed at ‘Stable’ |
|
Fitch |
Maintained at BBB- |
Maintained at ‘Stable’ |
|
Adani Electricity Mumbai Limited (subsidiary of AESL) |
S&P |
Reaffirmed at BBB- |
Upgraded to ‘Stable’ from ‘Negative’ |
Moody’s |
Reaffirmed at Baa3 |
Upgraded to ‘Stable’ from ‘Negative’ |
|
Fitch |
Maintained at BBB- |
Maintained at ‘Stable’ |
|
Adani Transmission Step One Limited (subsidiary of AESL) |
Moody’s |
Reaffirmed at Baa3 |
Upgraded to ‘Stable’ from ‘Negative’ |
Fitch |
Maintained at BBB- |
Maintained at ‘Stable’ |
|
Adani Energy Solutions Limited Restricted Group 1 – AESL RG1 |
Moody’s |
Reaffirmed at Baa3 |
Reaffirmed at ‘Stable’ |
Fitch |
Maintained at BBB- |
Maintained at ‘Stable’ |
|
Adani Green Energy Limited |
Moody’s |
Reaffirmed at Ba3 |
Upgraded to ‘Stable’ from ‘Negative’ |
Adani Green Energy Limited – RG1 |
S&P |
Maintained at BB- |
Maintained at ‘Stable’ |
Moody’s |
Reaffirmed at Ba2 |
Upgraded to ‘Stable’ from ‘Negative’ |
|
Fitch |
Maintained at BB+ |
Maintained at ‘Stable’ |
|
Adani Green Energy Limited – RG2 |
S&P |
Maintained at BB+ |
Maintained at ‘Stable’ |
Moody’s |
Reaffirmed at Ba1 |
Reaffirmed at ‘Stable’ |
|
Fitch |
Maintained at BBB- |
Maintained at ‘Stable’ |
|
(AESL: Adani Energy Solutions Limited) |
|||
The rating actions by both S&P and Moody’s now follows the same outlook that Fitch had reaffirmed as part of their review confirmed in CY2023 and all the international rating agencies now reflects the “Stable” outlook for all issuers within Adani universe.
Detailed press release of both agencies can be accessed through the following links.
S&P - https://disclosure.spglobal.com/ratings/en/regulatory/article/-/view/type/HTML/id/3114891
About Adani Portfolio
Headquartered in Ahmedabad, the Adani Portfolio is the largest and fastest-growing portfolio of diversified businesses in India with interests in logistics (seaports, airports, shipping and rail), resources, power generation and distribution, renewable energy, gas and infrastructure, agro (commodities, edible oil, food products, cold storage and grain silos), real estate, public transport infrastructure, consumer finance, defence, and other sectors. Adani owes its success and leadership position to its core philosophy of ‘Nation Building’ and ‘Growth with Goodness’, a guiding principle for sustainable growth. The Portfolio is committed to protecting the environment and improving communities through its CSR programmes based on the principles of sustainability, diversity, and shared values.
Further information at www.adani.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215968671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
